Boryeong, Promotes Introduction of Globally Approved New Drugs Not Yet Introduced Domestically with National Clinical Trial Support Foundation

Bae Byung-jun, Chairman of the National Clinical Trial Support Foundation (left), and Jang Doo-hyun, CEO of Boryung, are signing a business agreement and posing for a commemorative photo.
[Photo by Boryung]

[Asia Economy Reporter Lee Gwan-joo] Boryung announced on the 28th that it has signed a business agreement with the National Clinical Trial Support Foundation to introduce global pharmaceuticals not yet introduced in Korea.

This agreement was made to enhance accessibility to global new drugs, expand treatment opportunities for patients with rare and intractable diseases, and contribute to the improvement of public health.

According to the agreement, Boryung and the Foundation will share information on 244 global new drugs not yet introduced domestically and promote various collaborative projects such as joint research and academic events necessary for their introduction in Korea.

Byungjun Bae, Chairman of the National Clinical Trial Support Foundation, said, "I hope this agreement will serve as a productive opportunity to contribute to the introduction of overseas new drugs and improve treatment accessibility for domestic patients," adding, "Both organizations will actively cooperate to revitalize the introduction of overseas new drugs in Korea."

Jang Doohyun, CEO of Boryung, stated, "Introducing excellent overseas pharmaceuticals is as important a responsibility for pharmaceutical companies as new drug development in contributing to public health," and added, "We will strive to improve treatment outcomes through the introduction of overseas new drugs to offer some hope to patients suffering from rare and intractable diseases who have no suitable treatments domestically."

Boryung has continuously made efforts to introduce overseas new drugs domestically. Since 2017, Boryung has held exclusive domestic development and sales rights for 'Zepzelca' (active ingredient: lurbinectedin), a small cell lung cancer drug developed by the Spanish pharmaceutical company PharmaMar S.A. Zepzelca was designated as an orphan drug by the Ministry of Food and Drug Safety in July 2020 and received marketing approval in September this year, with plans to launch domestically in the first half of next year.